Global Ophthalmology Drugs Market Report 2017; New Report Launched
Development of combination therapies for the treatment of eye related diseases including glaucoma is an emerging trend in the market. For instance, in September 2013, Alcon (a subsidiary of Novartis) received FDA approval for commercialization of its Simbrinza, a fixed dose combination drug without beta blocker used for the treatment of glaucoma.
View full press release